Xtandi Archives -

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up

Bayer triples sales forecast for prostate cancer drug Nubeqa

https://pharmaphorum.com/news/bayer-triples-sales-forecast-for-prostate-cancer-drug-nubeqa/

Bayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track

Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer

https://pharmaphorum.com/news/trial-narrows-gap-between-bayers-nubeqa-and-rivals-in-prostate-cancer/

Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend

Xtandi takes fight to prostate cancer rivals with survival data

https://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/

Pfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a

Xtandi catches up with Erleada in castration-sensitive prostate cancer

https://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/

The EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug

EMA starts review of Xtandi in hormone-sensitive prostate cancer

https://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/

The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic

Prostate drug approved for use in non-metastatic cases

https://pharmaphorum.com/news/prostate-drug-approved-for-use-in-non-metastatic-cases/

Drug giant confirms press reports.

Pfizer confirms $14bn Medivation merger

https://pharmaphorum.com/news/pfizer-confirms-14bn-medivation-merger/

Xtandi